NKG2A Is a Marker for Acquisition of Regulatory Function by Human CD8+T Cells Activated With Anti-Cd3 Antibody

European Journal of Immunology - United Kingdom
doi 10.1002/eji.201041258
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Oral Anti-Cd3 Antibody Treatment Induces Regulatory T Cells and Inhibits the Development of Atherosclerosis in Mice

Circulation
Cardiovascular MedicinePhysiologyCardiology
2009English

Efficient Elimination of Chronic Lymphocytic Leukaemia B Cells by Autologous T Cells With a Bispecific Anti-Cd19/Anti-Cd3 Single-Chain Antibody Construct

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2003English

Anti-Nkg2a mAb Is a Checkpoint Inhibitor That Promotes Anti-Tumor Immunity by Unleashing Both T and NK Cells

Cell
BiochemistryGeneticsMolecular Biology
2018English

IL-2 Consumption by Highly Activated CD8 T Cells Induces Regulatory T-Cell Dysfunction in Patients With Hemophagocytic Lymphohistiocytosis

Journal of Allergy and Clinical Immunology
AllergyImmunology
2016English

Donor CD8+ T Cells Mediate Graft-Versus-Leukemia Activity Without Clinical Signs of Graft-Versus-Host Disease in Recipients Conditioned With Anti-Cd3 Monoclonal Antibody

Journal of Immunology
AllergyImmunology
2007English

Comprehensive Approach for Identifying the T Cell Subset Origin of CD3 and CD28 Antibody–Activated Chimeric Antigen Receptor–Modified T Cells

Journal of Immunology
AllergyImmunology
2017English

NKG2A Blockade Potentiates CD8 T Cell Immunity Induced by Cancer Vaccines

Cell
BiochemistryGeneticsMolecular Biology
2018English

Study of Enhancement of Anti-Tumor Effect by Lectin on LAK Cells Induced by rIL-2 With Anti-Cd3 Antibody.

Japanese Journal of Oral & Maxillofacial Surgery
1997English

Anti-Cd20 Therapy Depletes Activated Myelin-Specific CD8+ T Cells in Multiple Sclerosis

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy